Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2015 1
2018 1
2019 1
2020 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G. Slamon D, et al. N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488. N Engl J Med. 2024. PMID: 38507751 Clinical Trial.
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
Study of dijet events with a large rapidity gap between the two leading jets in pp collisions at s = 7 TeV.
Sirunyan AM, Tumasyan A, Adam W, Asilar E, Bergauer T, Brandstetter J, Brondolin E, Dragicevic M, Erö J, Flechl M, Friedl M, Frühwirth R, Ghete VM, Hartl C, Hörmann N, Hrubec J, Jeitler M, König A, Krätschmer I, Liko D, Matsushita T, Mikulec I, Rabady D, Rad N, Rahbaran B, Rohringer H, Schieck J, Strauss J, Waltenberger W, Wulz CE, Dvornikov O, Makarenko V, Mossolov V, Suarez Gonzalez J, Zykunov V, Shumeiko N, Alderweireldt S, De Wolf EA, Janssen X, Lauwers J, Van De Klundert M, Van Haevermaet H, Van Mechelen P, Van Remortel N, Van Spilbeeck A, Abu Zeid S, Blekman F, D'Hondt J, Daci N, De Bruyn I, Deroover K, Lowette S, Moortgat S, Moreels L, Olbrechts A, Python Q, Skovpen K, Tavernier S, Van Doninck W, Van Mulders P, Van Parijs I, Brun H, Clerbaux B, De Lentdecker G, Delannoy H, Fasanella G, Favart L, Goldouzian R, Grebenyuk A, Karapostoli G, Lenzi T, Léonard A, Luetic J, Maerschalk T, Marinov A, Randle-Conde A, Seva T, Vander Velde C, Vanlaer P, Vannerom D, Yonamine R, Zenoni F, Zhang F, Cimmino A, Cornelis T, Dobur D, Fagot A, Gul M, Khvastunov I, Poyraz D, Salva S, Schöfbeck R, Tytgat M, Van Driessche W, Yazgan E, Zaganidis N, Bakhshiansohi H, Beluffi C, Bondu O, Brochet S, Br… See abstract for full author list ➔ Sirunyan AM, et al. Eur Phys J C Part Fields. 2018;78(3):242. doi: 10.1140/epjc/s10052-018-5691-6. Epub 2018 Mar 21. Eur Phys J C Part Fields. 2018. PMID: 31264999 Free PMC article.
The data are compared to previous measurements at the Tevatron, and to perturbative quantum chromodynamics calculations based on the Balitsky-Fadin-Kuraev-Lipatov evolution equations, including different models of the non-perturbative gap survival probability....
The data are compared to previous measurements at the Tevatron, and to perturbative quantum chromodynamics calculations based on the Balitsk …
J/psi production and nuclear effects for d + Au and p + p collisions at square root of S(NN) = 200 GeV.
Adler SS, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Jamel A, Alexander J, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Atomssa ET, Averbeck R, Awes TC, Babintsev V, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bjorndal MT, Boissevain JG, Borel H, Brooks ML, Brown DS, Bruner N, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Camard X, Chand P, Chang WC, Chernichenko S, Chi CY, Chiba J, Chiu M, Choi IJ, Choudhury RK, Chujo T, Cianciolo V, Cobigo Y, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Cussonneau JP, d'Enterria D, Das K, David G, Deák F, Delagrange H, Denisov A, Deshpande A, Desmond EJ, Devismes A, Dietzsch O, Drachenberg JL, Drapier O, Drees A, Durum A, Dutta D, Dzhordzhadze V, Efremenko YV, En'yo H, Espagnon B, Esumi S, Fields DE, Finck C, Fleuret F, Fokin SL, Fox BD, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fukao Y, Fung SY, Gadrat S, Germain M, Glenn A, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gustafsson HA, Hachiya T, Haggerty JS, Hamagaki H, Hansen AG, Hartouni EP, Harvey M, Hasuko K, Hayano R, He X, Heffner… See abstract for full author list ➔ Adler SS, et al. Phys Rev Lett. 2006 Jan 13;96(1):012304. doi: 10.1103/PhysRevLett.96.012304. Epub 2006 Jan 10. Phys Rev Lett. 2006. PMID: 16486446
The observed nuclear dependence in d + Au collisions is found to be modest, suggesting that the absorption in the final state is weak and the shadowing of the gluon distributions is small and consistent with Dokshitzer-Gribov-Lipatov-Altarelli-Parisi-based parametrizations …
The observed nuclear dependence in d + Au collisions is found to be modest, suggesting that the absorption in the final state is weak and th …
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Thatcher N, et al. Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1. Lancet Oncol. 2015. PMID: 26045340 Free article. Clinical Trial.